A panacea for the Greek pharma tragedy
This article was originally published in Scrip
Greece’s significant financial crisis is doubtless turning into a tragedy for patients and pharmaceutical companies alike. Recent moves by the government to enforce lower prices and subsequent threats by drug manufacturers (among them Leo Pharma, Novo Nordisk and Norgine) either of non-compliance or potential withdrawal of products could be the precursor to litigation. However, it may be possible to salvage the situation, impose the price cuts and still stay within the confines of EU law.